Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Mendus, Audiocast with teleconference, Q3'24

By Inderes11/8/2024, 1:00 PM
Mendus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Eric
00:01 - 02:52

Thank you and welcome, everybody, to the Q3 webcast and also the business update that we can provide at this point in time. As a summary of Q3 and also some of the significant events that we reported after the reporting date, we have opened the first clinical centers for the AML 22 CADENCE trial. This is a trial run by the Australasian Leukaemia and Lymphoma Group, and they opened up the first centers in Australia, which we also communicated via LinkedIn yesterday. But we're happy that the trial is finally open for recruitment. We have worked with NorthX, our manufacturer, with whom we have a manufacturing alliance for the implementation of large-scale manufacturing of our lead product, vididencel. It's a crucial part of our preparations for pivotal stage readiness, and we are happy to report that the alliance is on track. The collaboration we announced in July with Institut Bergonié allows us to re-enter the clinic with our second clinical-stage product, Ilixadencel, and we will study this program in soft tissue sarcomas. Sarcomas will provide more background on that indication and the trial. During the call, we will have a presentation today supporting the combination of Ilixadencel and Avelumab at the SITC conference in Houston, Texas. We already published a press release yesterday with a summary of the main data supporting the combination of Ilixadencel and Avelumab. And Avelumab is also the antibody used in the REGOMUNE trial with Institut Bergonié. So it's very relevant data for that trial. We have also announced this week that we will present multiple abstracts at the upcoming conference of the American Society of Hematology. The ASH conference, which is from December 7th to 10th, will feature the most important update being the survival update of our ongoing Phase 2 trial, the ADVANCE II trial, on December 8th, for which we will issue a press release on Monday morning. On December 9th, with a summary of the survival update data. Then also as a final remark, as an update, we have extended our cash runway, so we've taken measures to further improve our cost efficiencies. Our CFO will comment in more detail, but it's important for us that we are preparing for Phase 3 readiness by mid next year, and also that we now have enough cash runway to deliver that milestone. And this is an improvement compared to earlier guidance, which indicated a cash runway only until the third quarter of 2025. As a summary for the financial information, I would like to hand it over to Lota.

Lota
02:53 - 04:47

Thank you. Eric. Yes. The net result for Q3 amounted to -23 million, and for the first nine months, the net result was 96.9 million. Cash flow from operating activities, which is normally closely linked to the net result, amounted to 20 million for Q3 and 73.1 million for the first nine months. The difference between the cash flow and the net result is mainly due to operating costs. We have a small income, and sometimes from grants. The main difference is then related to the cost we have for the manufacturing alliance with NorthX Biologics, which is prepaid, and therefore it will have no effect on the cash flow. So the cash flow will be lower. We were also forecasting that in the coming months the costs will increase. The cash position at the end of Q3 amounted to 109.3 million. And as Eric said before, we have explored some cost-saving measures to run the business more efficiently. We have lower clinical trial costs, as you might already be aware. We plan for another trial for ilixadencel, but then we got the opportunity to shift to the one we are now starting up with, Institut Bergonié. And that's a more cost-efficient trial. And then we are also optimizing cash management, and we are looking for grants that can fund some of the development costs. So yeah, that's everything from me.

Eric
04:49 - 14:35

Thanks for that. So as the next part of the presentation, we will provide some context about the cancer immunotherapy landscape and how our programs are positioned within this landscape. There are two reasons for that. One, we have made early decisions that serve as a general guiding principle for our programs, which we would like to explain in this part of the presentation. But also there have been major learnings recently in the cancer immunotherapy landscape, which I think are important for general awareness and also regarding the positioning of our programs. One of the main conceptions within the treatment of cancer has long been that the immune system is suffering significantly from treatments like chemotherapy, to the point that it is assumed to have no role in the treatment of cancer. However, checkpoint inhibitors, or immune checkpoint inhibitors, have revolutionized that concept. So when they were initially discovered, this class of antibodies showed long-term survival benefits in solid tumors that were very difficult to treat, such as melanoma and lung cancer, for example. The picture that you see on the bottom left shows what immunotherapy does. If you compare it to chemotherapy or targeted therapies based on small molecules or antibodies, targeted therapies have an immediate effect on cancer cells because they essentially slow down the growth of the cancer cells. So you see an immediate effect, but it's not a permanent effect. The effect is temporary, and it lasts as long as the treatment is working and is being applied. So we're talking about active immunity, which is built up by your own immune system. That leads to the formation of immunological memory and it leads to long-term survival benefit. There was a major finding: it holds up across many different tumor types, and for example, the largest-selling checkpoint inhibitor, Keytruda, has been approved in over 20 solid tumor indications and realized $25 billion of global revenues in 2023. However, only a minority of patients respond to checkpoint inhibitors, and it has been a major effort for the industry to improve the efficacy of checkpoint inhibitors by making more patients respond to them and, for example, combining them with other immunotherapy modalities. The tough, but in the end final conclusion is that it has been extremely difficult to improve the efficacy of checkpoint inhibitors where they are effective. So, somehow, the shift from the green line on the top right side to the blue line has not materialized. The survival of patients being treated with immune checkpoint inhibitors is still only benefitting 10 to 20% of patients, and some tumors are completely unresponsive to checkpoint inhibitors. So we decided quite early on that we would not pursue tumors that are already responding to checkpoint inhibitors because it has turned out to be so difficult. And we're talking about thousands of trials to elevate the level of patients responding to checkpoint inhibitors, and also the other way around where the checkpoint inhibitors are effective. It's very difficult to beat them because they are an effective immunotherapy. So we made an early decision to focus on tumors that do not respond to checkpoint inhibitors. And that positions us in bloodborne tumors, where we have vididencel as a lead product, and also, to a certain extent, in solid tumors that today respond very poorly to checkpoint inhibitors and for which checkpoint inhibitors have not been approved. Active immunity is immunity built up by our own immune system. It's also the only long-lasting form of immunity. It takes some time to build up because the immune system has to recognize, in this case, a vaccine or an earlier disease, and it takes time to build up an immune response, and then also to build up immunological memories or cells that have long persistence and that can always quickly respond when the disease comes back. So you need to do this in a low disease setting. That's also been one of the major choices we've made as a company. Regarding our positioning in the market. We focus on low disease settings where there is a big risk of recurrence, but where also the immune system still has a chance to build up sufficient immunity to provide immune control over a longer period of time against the residual disease. The market for low bone tumors is significant. So when we look into the current market for immune checkpoint inhibitors, that focuses only on solid tumors. We're talking about a market of a total size of around $47 to $37 billion. But when we look into the addressable bloodborne tumor market, and this is an exercise we did in-house with external consultants, it's been quite extensive market research. We assessed the market to be roughly $16 billion in the bloodborne tumor space, solely for Vididencel. We are currently, of course, only addressing a small part of that market. So we're addressing acute myeloid leukemia as a bloodborne tumor. We're addressing patients who have undergone chemotherapy for acute myeloid leukemia. But still, that is a very sizable market because there is a need for this kind of treatment in bloodborne tumors, including acute myeloid leukemia. So this provides some context on how we think and how we have positioned our programs. So let's now move to the actual programs. Vididencel is addressing AML and particularly the need for maintenance therapies in AML. AML is a very aggressive tumor. Actually, the only way to reduce the disease is with high-intensity chemotherapy. And nowadays also with a new drug called venetoclax, which is also a very toxic compound. But it reduces the number of circulating cancer cells. However, the big problem with AML, and the reason why it's such a deadly disease, is relapse. So basically, if you stop treatment, relapse is almost immediate. The only way to permanently get rid of acute myeloid leukemia is through a hematopoietic stem cell transplant or bone marrow transplant. And even in that situation, half of the patients suffer from a relapse, which is also the main reason for transplant failure. So it's a very deadly disease. You need to keep it under control. And for long-term control of the disease, you need what's called maintenance treatment. Another very important element of maintenance treatment is that it is safe. You can't provide more toxic treatments after patients have already suffered from very toxic treatments like high-intensity chemo or venetoclax to get the disease down. So maintenance treatment needs to deliver durable responses, but it also needs to preserve health and quality of life. And that's where immunotherapy can make a difference. This is the survival curve that you know we've presented before. But in the context of what we just described, you can appreciate what's going on. We see a number of patients. In our case, we treated 20 patients, and six of them relapsed, eventually passing away relatively quickly after treatment. Those were patients that had poor immunity, poor immune responses. And we're unfortunately not able to build up immunity against the residual disease. The promising part of the trial is that 14 patients were alive at the end of the trial at 72 weeks, and we are now following up these patients in long-term follow-up. And the long term follow-up that you see is in years. So we get a really different picture for these patients that have a good immune response. And that translates into the control of residual disease and long-term survival, with 11 out of 20 patients still in the first complete remission without further treatment. It was also confirmed in the first half of this year that the immune responses and the general status of the immune system are associated with the clinical benefit, which is a very important element of the proof of concept for this product as an active immunotherapy in AML. And what you see is that all the patients who had good levels of B cells and good levels of T cell responses are in the long-term survival part of the curve, confirming that the immune responses we detect actually translate into a survival benefit. This is a chemical drug called Azacitidine. It's now approved as a maintenance treatment in the form of an oral tablet, Azacitidine. And here you see a very different picture. So this is a picture of MRD positive AML patients. We also, in our advanced two trial we just discussed, only treated patients with measurable residual disease or MRD Mid, which puts patients in the high-risk patient category. This is from a Phase 3 trial run by BMS, the large pharmaceutical company. And what you see is that patients with an MRD positive status have a very poor prognosis. And this is after high-intensity chemotherapy. Median relapse-free survival. So the time until patients get sick again is 2.7 months. So more than half of the patients are already sick again within three months. And with Azacitidine, you slow down that progression. So it shifts to seven months. But in the context of what we just discussed about the relevance of immunotherapy, you can see what's happening. This is a slowing down of the disease and it's not leading to long-term survival benefits. But this is the only approved maintenance therapy today. There's a good medical rationale to combine vididencel with oral azacitidine. And that is also supported by data we have generated in-house, part of which we will also present at ASH this.

Unknown 1
14:35 - 14:36

Is it here?

Eric
14:36 - 29:03

That Azacitidine is actually synergistic and does not negatively affect the mode of action of vididencel. So the two drugs can be effectively combined. And they also both have a very good safety profile, making the combination suitable for maintenance therapy. The trial we have engaged in with the Australasian Leukaemia and Lymphoma Group (ALLG) is called the AML M22 CADENCE trial or, in short, the CADENCE trial. This trial is run by ALLG. It's important to emphasize it's not our trial. We facilitate the trial. We provide, um, vididencel for clinical use. We provide some financial support for the logistics involved in the trial. But in the end, ALLG is responsible for the execution of the trial. For us, this brings two important elements: one, this is a relatively large trial, involving up to 140 patients. It's a two-stage trial. First 40 patients for safety analysis and then another 100 patients for a proof of concept or feasibility stage. Secondly, the data from this trial can be used for our global registration dossier of the product. Particularly, the safety data will be valuable because this is the first trial where we directly combine oral Azacitidine with vididencel. We have announced it, and yesterday we made some social media efforts around it based on a release by ALLG. But also in the Q3 report, you can see we announced that the first sites are now open. Also, we should say that it's a little bit later than we had hoped for. We had already, um, achieved ethical committee approval in March, but again, it's up to ALLG to execute on the trial. We can only facilitate, and we are very happy that they are highly motivated to conduct this trial, having now opened the first clinical centers to allow for patient recruitment. The overall picture is this: we have the ongoing ADVANCE II trial, the trial for which we showed the survival curve. The next survival update will be on December 8th during the ASH conference. Again, the press release will be on the morning of December 9th, but that is an important update. There's also an abstract already available on the ASH website, but that is the update with the date. The data we could collect is up to May of this year, so the actual data by the year end, and also the actual summary of the survival data that we can make will be made available on December 8th. And then, a press release was issued on December 9th. The AML CADENCE trial, as I explained, is now open for recruitment. It will be a very valuable trial in terms of size, but also in terms of the data that we can get out of that trial to benefit our global registration dossier. But the biggest effort currently for the company is in the preparation of a pivotal stage development program, which means this is the last phase that you need to go through with the product to get it registered. In the end, commercialization. And the reason it takes some time is that it comprises different steps. On the one hand, we are working on a clinical trial protocol, and we're asking the regulators, like the EMA and the FDA, for feedback on the protocol. But also we need to make sure that we have the final production process in place. And we have actually manufactured the first GMP batches for clinical use based on that large-scale manufacturing process before we can engage in the pivotal stage development trial. And the reason is that during such a trial, you want to change as little as possible in your manufacturing process. So, we are now working on that with our manufacturing partners at NorthX Biologics. That's why it's also so important that the Manufacturing Alliance is on track. And also in the Q3 report, we have asked our Chief Technology Officer, Leopold Bethea, to give an interview to provide a bit more insight into how that collaboration is working and what the relevance is for the further development of Vididencel. Now, based on all the preparations, the alignment with the regulators, and being ready for large-scale GMP manufacturing, we estimate to be in the position to be pivotal stage ready, meaning the product is ready to enter the pivotal stage trial by mid next year. And then, of course, we have to engage in such a trial, either by ourselves, with a partner, or a combination of both. And that is the next step. For now, we are fully focused on executing towards this pivotal stage readiness. Then, as a last remark about the development path for Vididencel, the maintenance population in AML is much broader than the post-chemo patients, and we are considering additional AML maintenance indications. And also we are doing some exploratory work to look into adjacent indications, like, for example, chronic myeloid leukemia. This is the kind of data we are currently investigating and accumulating in our research labs, and which we will also, to a certain extent, present at the upcoming ASH conference. So this is the overall AML treatment landscape. Like I said in the beginning, there's high-intensity chemotherapy for eligible patients, which constitutes roughly 50% of the total AML patient population. These are the patients we are currently treating. Importantly, transplants are the only potentially curative option, but they're not available for the majority of patients. So all the patients who are not eligible or unable to timely access a transplant can be treated with our products. And we will now do that in combination with oral azacitidine. And we have already initiated the CADENCE trial to explore that combination. But that will also be the basis for the registration trial moving forward that we are preparing independently for ourselves. Then also in the post-transplant setting. So the post-HCT setting. Patients have a higher risk of relapse. So it could serve as a rationale to. Boost those transplants with an anti-leukemic vaccination, which is what we provide with Vididencel. So that's another part of the patient population. AML patients that could benefit from this product. And then finally, we have the patients that are classified as chemo-unfit who are today treated with a combination of Azacitidine and venetoclax, with Venetoclax being quite an effective drug to drive more patients into a complete remission, but also being relatively toxic. So those patients will have a much better chance today, with venetoclax being available, of reaching a complete remission. But in the end, those patients will also require maintenance therapy. And this is one of the reasons we also did preclinical work to explore the combination of Azacitidine and Venetoclax with our product, Vididencel, and we're able to show very nicely at ASH that there's a good combination rationale between the two. Uh, therapy. On the one hand, and Vididencel on the other hand. Then moving to the other programs, the ovarian cancer trial we have ongoing with the University Medical Center in Groningen. It's going well. We have established in the majority of patients immune responses and also very good safety of the product. And what we will do in the fourth quarter of this year is to evaluate the immune responses in all patients treated, and that's also the primary readout of the trial. So we aim to collect those data via the University Medical Center in Groningen before the year end, and report those topline data before the year end. Uh, I should also say, because I read from some of the analysts covering us, that, that, that this would already be the long-term survival. That's not the long-term survival follow-up. So where we are now, also looking back to the introduction I provided about cancer immunotherapy, is in the initial phase. So we've treated all the patients. We've progressed to week 22 in analyzing the patients' responses. And we saw that ten out of seventeen patients had stable disease at week 22. We have established that in the majority of patients, there are immune responses directed against relevant tumor antigens, and the product is safe. Now we need to look long term. If the patients are responding and are becoming more stable as compared to what you may expect in this indication, and that's the phase that will be next. So in the fourth quarter, we will not report long-term survival data, but we will report the outcome for all the patients treated to date. And then we will look for, of course, the long-term follow-up of these patients to see if there's actually a number of patients benefiting from long-term survival benefit after treatment with Vididencel. So in this indication, the initial data look good. We have to look more carefully for an efficacy signal. Then moving to Ilixadencel, Ilixadencel is an intratumoral primer. It's a different kind of product. Vididencel is based on a cell line, and we can grow large quantities of these cells, which we then transform into the final product that has a dendritic cell phenotype. Ilixadencel is actually derived from healthy donor monocytes, extracted from healthy donor blood, and from which we derive the product. And then we inject these activated dendritic cells into a tumor. And they improve the intratumoral inflammatory environment. So it facilitates the immune system to act against tumor cells and also enhances the presentation of tumor antigens to the immune system. Now we've tested this concept in a wide range of tumors. And all of these tumors were very difficult to treat. And as part of the strategy I summarized earlier, we have now shifted towards an indication that is not responding to checkpoint inhibitors currently, which is soft tissue sarcoma. So the rationale to explore ilixadencel in soft tissue sarcomas. It's a very difficult-to-treat tumor type. It's also a very aggressive tumor. So particularly when there's first-line treatment failure, these tumors become very unresponsive to currently available therapies, including immune checkpoint inhibitors. But also, it contributes to progression. And eventually, death is, in that sense, quite a significant outcome, highlighting it's a very aggressive tumor. Now, one of the encouraging elements of soft tissue sarcomas. And this is also a study done, uh, with authors from Institut Bergonié. So the institute we are working with, including Professor Antoine Italiano, shows that you do see a survival benefit in patients that have high numbers of infiltrating lymphocytes, particularly what's called tertiary lymphoid structures, which are associated with functional immune responses. Additionally, improved clinical outcomes in soft tissue sarcoma are associated with patients treated with immune checkpoint inhibitors. Now, that makes a very logical combination with ilixadencel because it will create a more pro-inflammatory immune environment inside the tumor, and it will attract more immune cells inside the tumor. We've already demonstrated that Ilixadencel is safe and can potentially act synergistically with immune checkpoint inhibitors, including anti-CTLA-4 and anti-PD-1 antibodies. Uh, but that trial was completed. It was, uh, with a positive safety readout. What we are now presenting today at SITC is the combination with Avelumab. And Avelumab is an anti-PD-L1 antibody. And what we will show at SITC is that there's a strong synergy between ilixadencel and Avelumab. And actually, the addition of Avelumab leads to better activation of NK cells. Other immune cells, and also the activation of bystander dendritic cells, facilitate a systemic immune response against the tumor antigens that are part of the tumor. So in that sense, we have built up, I think, a strong case to support this trial, and we're looking forward to going ahead with this trial. We announced the collaboration with Institut Bergonié in July. It will be a multicenter, open-label Phase 1/2 trial. There are a large number of leading French hospitals involved. The trial is supported by Bayer, which provides Regorafenib, and Merck, which provides avelumab. And what we will do is provide ilixadencel specifically for the study arm, addressing soft tissue sarcomas and allowing Institut Bergonié to, as part of the REGOMUNE trial, treat up to 43 soft tissue sarcoma patients. We are currently in the preparation phase, which we aim to complete by Q4 2024. So this quarter, it means that we are submitting all the regulatory documents needed to get the trial started in the first half of next year. And of course, also ensuring that we have enough study material and we work closely together with Bergonié to get this trial started. So as a summary and outlook, the advanced two data is pivotal in our findings. The combination of the survival data and the immune monitoring data provides proof of concept that Vididencel acts as an active immunotherapy in AML. And I hope we also provided some additional context about the meaning and the importance of that statement. We are combining with oral azacitidine in the AML M22 CADENCE trial that is run by the Australasian Leukaemia and Lymphoma Group (ALLG). But very importantly, we are not dependent on this trial. We are benefiting from this trial, but we are separately preparing for a registration trial for vididencel in AML, and that includes feedback from the regulatory agencies. It includes the implementation of large-scale manufacturing, and we aim to be ready to enter into a phase three trial in the second half of next year. This whole exercise is supported by a strong regulatory dossier, including orphan drug designation and Fast Track Designation, but also, for example, a GMP certificate issued by the EMA for the manufacturing process and the preclinical data of the product. It's a very important validation of our approach towards manufacturing, and we will have the next survival update of the ADVANCE-2 trial on December 8th at ASH. And I hope we also provided a good picture today, showing that the other programs, including the Allison trial and the Ilixadencel program, as well as our preclinical pipeline program based on NK cells, are well positioned to deliver additional upside. With that, we conclude the update for Q3 and the business update, and the meeting is now open for questions.

Operator
29:09 - 29:28

If you wish to ask a question, please dial pound five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Qian Shen Li from Pareto Securities. Please go ahead.

Qian Shen Li
29:29 - 29:57

Hi. Good afternoon and thanks for the update. So a few questions from me. According to the abstract you published earlier this week, I think it's quite encouraging to see there's only one additional death, and the median overall survival has not been reached yet. But for the survival update that you are going to present in December, is it fair to assume that the new data cutoff will be until November?

Eric
29:59 - 31:02

Yes. Hey, Qian, thanks for joining. Yeah. One patient passed away during the trial. Yeah, that was years after the initial treatment success, by the way. But of course, there are multiple reasons why patients can, in the end, pass away. And often, these patients are also somewhat older. Uh, but the overall picture that you see now in the abstract is indeed the data we collected in May from all the hospitals that are following up with the patients in long-term follow-up. So these patients come to the hospital, um, at least twice a year. And that is also the moment when we can collect the data from all the hospitals. So the actual update at ASH will provide more comprehensive data. But you have to submit the abstracts to ASH already in early June. So that's why the best thing we could do at that point in time was to provide the intermediate update that we could collect in May. The real update we will present at ASH is indeed based on the data we have collected from all the hospitals, and we are currently compiling it to present at ASH.

Qian Shen Li
31:03 - 31:17

So, um, uh, one patient passed away in the trial, and, uh. So, um, uh, one patient passed away in the trial, and, uh. And I also noticed that there are three patients who seem to undergo the stem cell transplant. So how are you thinking of presenting the data? We exclude these patients in the next update.

Eric
31:19 - 32:06

Yeah. Excellent question, Chen. In the survival curve that we presented during this webcast call, we also censor those survival plots, the Kaplan-Meier plots, for the transplanted patients. So it's a conservative way to do it. What you often see is that studies do not discriminate between the transplanted patients and the non-transplanted patients, but in our case, we really wanted to look at monotherapy efficacy. What happened was all the patients that were recruited for the advanced two trial were, at the time of recruitment, not eligible for transplant or there was no transplant available. And what happens if, after vaccination with vididencel or treatment with vididencel, the patients have more time, so they recover? Their health is better.

Unknown 2
32:06 - 32:06

They're in a.

Eric
32:06 - 32:06

Relatively.

Unknown 2
32:06 - 32:07

Stable.

Eric
32:07 - 32:48

Phase then? Yeah. Doctors sometimes just don't want to take the chance. And they look for a transplant and they proceed with the transplant. The good news is that the transplants were successful. So it's also important for us to ensure that we don't compromise a potential curative option for AML patients with our product. The transplant went well. But what we typically do is clearly mark how we report the numbers. And also in the case of our current overview, you can see that the 11 patients are still in first complete remission. The 14 patients, which are now 13 patients alive, included the transplanted patients. But we will also clearly, let's say, differentiate the way we report the outcome of the trial.

Qian Shen Li
32:48 - 32:51

And they look for a transplant and they perform the transplant. And they look for a transplant and they do the transplant. Thanks for taking my question.

Eric
32:52 - 32:55

You're welcome. Thanks for joining, Jen. I think we don't hear.

Operator
32:57 - 32:59

From Edison Group. Please go ahead.

Christian Binder
33:00 - 33:19

Hi there. Thanks very much for taking my question and thanks for the presentation. I noticed in the results that R&D expenses were notably lower than in Q1 and Q2. I'm curious to know to what extent this is due to the NorthX technology transfer nearing completion, and if so, might we expect this trend to continue in Q4?

Lota
33:19 - 33:51

Yes, I can address that question. It is like this with the R&D costs. And where we report the cost for the tech transfer, it goes up and down according to activities. In Q3, we had the vacation period. So NorthX has closed the factory for two weeks for a maintenance stop. And also there were some adjustments made to the schedules. Therefore, there was lower activity in Q3. So it's not always possible to compare the quarters to each other.

Christian Binder
33:52 - 34:20

And they look for a transplant and they do the transplant. And they look for a transplant and they do the transplant. And my second question, um, I'm really looking at the Alison and advance two readouts, which we're looking forward to. Just curious to know that given AML is the strategic priority, what might the next steps look like in ovarian cancer following the Alison readout? And I think you touched upon it. But after the subsequent long-term survival data, can you provide a bit more clarity on how these might be prioritized moving forward?

Eric
34:22 - 35:33

Hi. Yeah, absolutely. I think, uh, um, like I said, ovarian cancer is an aggressive disease, but it's a slower disease than AML. With ovarian cancer, we're looking at a very different picture. So women are either healthy or they come back to the hospital and don't feel well. And then you have to look at whether there's tumor recurrence or if already present metastases have grown. So it takes more time to read out such a trial. And also, given that we have our major efforts currently ongoing in AML, that's the clear priority for the company and for the ovarian cancer trial. We'll just see if we can pick up a clear sign of survival benefit, in which case that could be an interesting indication to pursue, either with the product as monotherapy or in combination, for example, with other drugs that are currently being developed for ovarian cancer. Uh, but first and foremost, we want to see if we can really pick up, uh, a survival benefit before we take other decisions. And that will take at least another 12 months.

Christian Binder
35:34 - 36:04

That's great. And my second question, um, looking really at the Alison advance two readouts which we're looking forward to. Thanks, Eric. Um, my my last question is just looking at the CADENCE trial, um, given the sort of slight pushback which you touched upon, which we appreciate comes from ALLG, mainly given that they're in control. But just curious to know if this has any influence on the planned timelines for the Registrational trial. I think the current guidance is consistent with your previous communication. Is it fair to say now that the sites are active, and we can assume a reduced risk of any other possible delays? And my second question, um, really looking at the Alison and Advance Two readouts which we're looking forward to.

Eric
36:04 - 37:37

Yeah. Thanks for asking the question. Well, first of all, again, the trial is in the hands of ALLG. We're very happy with the collaboration. They're a very high-quality research group and also have high-quality clinical centers supporting ALLG. What caused a bit of a delay compared to our earlier expectation was the time between the ethics committee approval and the actual opening of the hospitals, which was due to organizational and communication elements. But one way or the other, ALLG is committed to the trial. And they've now, of course, opened the first center. So we expect, and they've also stated in their own social media post yesterday, that they will continue to open up additional centers. And we've stated in the past that there will be up to nine clinical centers to support the first stage of the trial. So I think we've taken the first and most important step, which is that the hospitals are opening up now. There is no correlation between the tempo of the CADENCE trial and the phase three trial. That's the other element I wanted to emphasize and will emphasize. Again, we are at full speed on track preparing for a phase three trial. We prepare that trial on the basis of the ADVANCE II data that we discussed today. We will benefit from the CADENCE trial, but we are not dependent on it. The preparations for the phase three trial are dependent on two important elements, which is one the trial design and the alignment with the regulators. And it's two, the completion of the large scale GMP manufacturing in our alliance with NorthX Biologics. Those two elements coming together will make us pivotal-stage ready. That's not dependent on the CADENCE trial.

Christian Binder
37:38 - 37:41

Fantastic. That's very helpful. Thank you very much.

Eric
37:41 - 37:43

Welcome. Thanks for joining.

Operator
37:45 - 37:49

The next question comes from Christian Binder from Ready. Please go ahead.

Unknown 3
37:50 - 38:08

Hi. Thanks so much for taking my questions and sorry for the initial technical difficulties. Um, but just to follow up on CADENCE, as mentioned, it's not your trial, it's ALLG's. But given the slight delay in site activation, can you provide any updated indications regarding when we might see the initial readouts?

Eric
38:08 - 39:46

Well, I don't think we are, at this point, considering a delayed readout. There are two main reasons for that question. One is that you typically see a kind of hockey stick effect. It takes the most time to get the first sites initiated and to get the doctors and study nurses working with the product, etc. , and creating patient awareness. Next week is a very important week because it is the week of the ALG Scientific Days. There will be a plenary presentation of the AML 22 CADENCE trial starting this week. Actually, yesterday the ALLG started communicating about the trial. So it's a combination of actually opening the hospitals, training the personnel to work with the product, and creating awareness, which usually takes most of the time in the start-up phase of such a trial. But at this point, we do not expect that it will, let's say, result in further delays. I think we've now taken the first steps, and we will follow up and see ALLG follow up with the opening of additional clinical centers and starting with patient recruitment. So I think we will still stick to the idea that we will have the initial data in the first half of 2026. It's also an open-label trial. So the first stage is immediately delivering data on the safety of the combination Vididencel and oral Azacitidine. And that's particularly the information that we are looking for, also to gain more confidence, let's say, in advance of the Phase 3 trial about the combination. So in that sense, we're also not dependent on the actual completion of the first stage of the CADENCE trial. The data that relate to, uh, let's say the safety of the combination will come in basically from the start of treating patients.

Unknown 3
39:47 - 40:12

Perfect. That's really helpful. And I just want to follow up on your cost-saving measures. You mentioned no clinical trial costs. Primarily because you're conducting the REGOMUNE trial now instead of an in-house trial with Ilixadencel. So just to clarify, um, I guess you didn't really scale back your ambitions there. It's just that this form of trial, um, means lower costs for you.

Eric
40:12 - 41:57

Actually, yesterday the ALLG started communicating about the trial. I think that's exactly the right summary question. And we actually looked into different ways to conduct a sizable trial with Ilixadencel. Obviously, you know, we also keep an eye on the priorities that we need to follow as a company based on available data. And with ilixadencel, I think we have collected a lot of promising but early clinical signs of efficacy. And yes, that makes it a program that we want to pursue. Uh, but we have to balance it with our efforts to prepare the AML program, where we now see a very clear efficacy signal, uh, for phase three. So we were initially considering a company-sponsored trial. Then we shifted to an investigator-sponsored trial, and we were initially talking to another hospital. Then came the connection with Institut Bergonié, presenting the possibility to be part of the REGOMUNE trial, which involves a combination of drugs that we are very pleased with. And now, we of course also have more specific available preclinical data. But the trial setup, with the indication being soft tissue sarcoma, and the fact that we can work with Bergonié, was a tremendous opportunity. Also, what we hope to show today is that Bergonié is a center that knows a lot about the immunology and also particularly the intratumoral immunology of this kind of indication. So it was a perfect setting, first of all, and secondly, because the trial is up and running and we only contribute the study drug. So that makes it a very cost-efficient trial. So the combination of a high-quality trial, a substantial number of patients we can treat in that trial, and the cost made this the best possible setting to move forward with the product.

Unknown 3
41:58 - 42:00

Perfect. That was all from my side. Thank you so much.

Eric
42:02 - 42:03

Thanks, Christian.

Operator
42:04 - 42:13

There are no more questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

Eric
42:14 - 42:49

Thank you. Operator. Um, I think there's one specific question in the activity feed about the nomination committee press release we just issued and whether or not specific parties are part of that. I think that is their discretionary decision, whether or not they want to spend the time on the nomination committee. Yes or no. So I can't comment on that in more detail. But thanks for asking the question. I don't see any further questions in the activity feed. So with that, I would like to close this call and thank everybody for their participation.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…